Inflammation

The aim of this study was to assess cytokine levels in patients with refractory chronic rhinosinusitis with nasal polyps and to identify inflammatory markers associated with certain subtypes.

Results from 2 large clinical trials show that dupilumab is associated with clinical improvements in symptoms of chronic rhinosinusitis (CRS) with nasal polyps.

Results of a subgroup analysis within a randomized, controlled trial show that the monoclonal antibody dupilumab (Dupixent) improved clinical and patient-reported outcomes among patients with chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma.

Avoid the allergen. For decades, that was the only advice for people with life threatening food allergies. While that is still true, the food allergy community is cautiously, but excitedly, watching research unfold that could help patients tolerate more of the allergen that might otherwise have serious or deadly consequences.

Patients with atopic dermatitis (AD) have a significantly greater risk for additional atopic diseases, as well as significantly greater healthcare resource utilization and total cost compared with adults without AD. The burden of AD was generally comparable to that of psoriasis, although patients with AD reported increased use of emergency room visits compared with patients with psoriasis.

A recent study in The American Journal of Clinical Dermatology led by Igor Snast, MD, sought to evaluate the efficacy and safety of biologic agents in the treatment of atopic dermatitis (AD). The results of the study showed that in particular, dupilumab stood out.

A meta-analysis finds a connection between atopic dermatitis and occupational hand eczema.

Dupilumab's effectiveness is due to the monoclonal antibody's ability to rapidly reduce inflammation.